RPRX vs. BGNE, ALNY, CTLT, JAZZ, HZNP, PRGO, CORT, SUPN, PCRX, and NKTR
Should you be buying Royalty Pharma stock or one of its competitors? The main competitors of Royalty Pharma include BeiGene (BGNE), Alnylam Pharmaceuticals (ALNY), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics Public (HZNP), Perrigo (PRGO), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), and Nektar Therapeutics (NKTR).
BeiGene (NASDAQ:BGNE) and Royalty Pharma (NASDAQ:RPRX) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, community ranking, dividends, earnings, institutional ownership and analyst recommendations.
BeiGene received 224 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 69.14% of users gave BeiGene an outperform vote while only 67.96% of users gave Royalty Pharma an outperform vote.
In the previous week, Royalty Pharma had 3 more articles in the media than BeiGene. MarketBeat recorded 9 mentions for Royalty Pharma and 6 mentions for BeiGene. BeiGene's average media sentiment score of 1.26 beat Royalty Pharma's score of 1.17 indicating that Royalty Pharma is being referred to more favorably in the news media.
Royalty Pharma has lower revenue, but higher earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.
48.6% of BeiGene shares are held by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are held by institutional investors. 7.4% of BeiGene shares are held by company insiders. Comparatively, 18.9% of Royalty Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
BeiGene presently has a consensus price target of $251.93, suggesting a potential upside of 69.25%. Royalty Pharma has a consensus price target of $46.75, suggesting a potential upside of 70.56%. Given BeiGene's stronger consensus rating and higher possible upside, analysts plainly believe Royalty Pharma is more favorable than BeiGene.
Royalty Pharma has a net margin of 35.70% compared to Royalty Pharma's net margin of -28.39%. BeiGene's return on equity of 22.94% beat Royalty Pharma's return on equity.
BeiGene has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.
Summary
Royalty Pharma beats BeiGene on 13 of the 18 factors compared between the two stocks.
Get Royalty Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for RPRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Royalty Pharma Competitors List
Related Companies and Tools
